MiRNA-488-3p inhibits malignant progression of NSCLC by modulating ADAM9.

Wu Y, Wu Y, Chen XY, Niu YX, Lv FZ, Gao W.

DOI: 10.26355/eurrev_202009_22830
Published: 2020-09-01
Container: Eur Rev Med Pharmacol Sci
Publisher: Not recorded
Open access: no

Credibility signals

serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.26355/eurrev_202009_22830,
  title = {MiRNA-488-3p inhibits malignant progression of NSCLC by modulating ADAM9.},
  author = {Wu Y and  Wu Y and  Chen XY and  Niu YX and  Lv FZ and  Gao W.},
  year = {2020},
  journal = {Eur Rev Med Pharmacol Sci},
  doi = {10.26355/eurrev_202009_22830},
  url = {https://doi.org/10.26355/eurrev_202009_22830}
}

RIS

TY  - JOUR
TI  - MiRNA-488-3p inhibits malignant progression of NSCLC by modulating ADAM9.
AU  - Wu Y
AU  -  Wu Y
AU  -  Chen XY
AU  -  Niu YX
AU  -  Lv FZ
AU  -  Gao W.
PY  - 2020
JO  - Eur Rev Med Pharmacol Sci
DO  - 10.26355/eurrev_202009_22830
UR  - https://doi.org/10.26355/eurrev_202009_22830
ER  -

APA

Y, W., Y, W., XY, C., YX, N., FZ, L., & W., G. (2020). MiRNA-488-3p inhibits malignant progression of NSCLC by modulating ADAM9.. Eur Rev Med Pharmacol Sci. https://doi.org/10.26355/eurrev_202009_22830

Source records

europe-pmc · retrieved 2026-09-25T07:26:33.402Z